Shibo Jiang

6727240, Apr 27, 2004

Oct 21, 1994

08/342745

Alexander R. Neurath - New York NY
Shibo Jiang - New York NY
Asim Kumar Debnath - New York NY

New York Blood Center, Inc. - New York NY

A61K 31555

514185

A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.

20100021427, Jan 28, 2010

May 29, 2009

12/474702

Xin Chen - Tianjin, CN
Linqi Zhang - Edison NJ, US
Shibo Jiang - New York City NY, US

Tianjin FusoGen Pharmaceuticals, Inc. - Tianjin

A61K 38/16
A61P 31/18
A61K 38/21

424 855, 514 12, 424 856, 424 857

The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.

20120100150, Apr 26, 2012

Oct 20, 2011

13/277515

Shibo Jiang - New York NY, US
Lanying Du - Rego Park NY, US
Yusen Zhou - Beijing, CN

NEW YORK BLOOD CENTER, INC. - New York NY

A61K 39/42
A61P 31/16
C07K 16/10

4241471, 5303883, 5303873

Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.

59852755, Nov 16, 1999

Sep 29, 1995

8/537245

Alexander Robert Neurath - New York NY
Asim Kumar Debnath - New York NY
Shibo Jiang - Jackson Heights NY

New York Blood Center - New York NY

A61K 3520

4241331

A composition is provided which comprises a protein or peptide containing lysines, wherein at least one of the lysines and/or the N-terminal amino group of the protein or peptide, such as casein,. beta. -lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride. Additionally a composition is provided wherein a protein or peptide containing arginines is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal. The compositions are capable of binding to CD4 cell receptors, such as the HIV-1 or HIV-2 binding site on CD4 cell receptors. The compositions are thus useful for the prevention of HIV-1 or HIV-2 infection, especially by local administration.

59853131, Nov 16, 1999

Jul 8, 1998

9/112130

Alexander Robert Neurath - New York NY
Asim Kumar Debnath - Fort Lee NJ
Shibo Jiang - New York NY
Nathan Strick - Oceanside NY
Gordon Jay Dow - Santa Rosa CA

New York Blood Center, Inc. - New York NY

A61F 1302
A61F 606
A61F 614
A61K 916

424434

A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

59520094, Sep 14, 1999

Aug 28, 1996

8/703925

Alexander Robert Neurath - New York NY
Asim Kumar Debnath - New York NY
Shibo Jiang - Jackson Heights NY

New York Blood Center - New York NY

A61K 3520

424535

A method of preventing the transmission of or treating herpesvirus, such as herpes simplex virus infection, or Chlamydia trachomatis comprising administering to a patient a composition which comprises: (i) a protein or peptide containing lysines and an N-terminal amino group, wherein at least one of the lysines or the N-terminal amino group of the protein or peptide, such as casein,. beta. -lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride and/or (ii) a protein or peptide containing arginines, which is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal.

57982066, Aug 25, 1998

Jan 10, 1997

8/782044

Alexander Robert Neurath - New York NY
Asim Kumar Debnath - New York NY
Shibo Jiang - Jackson Heights NY
Yun-Yao Li - Flushing NY
Nathan Strick - Oceanside NY

New York Blood Center - New York NY

C12Q 170
G01N 3353

435 5

A method for the screening of a test compound for inhibiting the binding of a CD4-HIV 1 complex to HIV-1 second receptors, comprising: (a) preparing a magnetic ligand by mixing a magnetic, CD4-containing substrate with HIV-1, (b) mixing the magnetic ligand from step (a) with a test compound, (c) adding cells that express the HIV-1 second receptors to the mixture from step (b), (d) separating cells with bound magnetic ligands from cells without bound magnetic ligands by contact with a magnetic separator, and (e) quantifying the cells with bound magnetic ligands and quantifying the cells without bound magnetic ligands.

54440440, Aug 22, 1995

Mar 26, 1992

7/859923

Shibo Jiang - New York NY
Kang Lin - New York NY
A. Robert Neurath - New York NY

New York Blood Center - New York NY

A61K 3800
C07K 500
C07K 700
C07K 1700

514 12

A synthetic HIV-1-based polypeptide as well as methods for topically inhibiting HIV-1 infectivity or replication. The polypeptide of the present invention has an amino acid sequence substantially corresponding to a specified region of the HIV-1. sub. IIIB virus. The polypeptide of the present invention may be administered in effective amounts for topically inhibiting HIV-1 infectivity or replication. The polypeptide is useful for inhibiting the replication of the HIV-1 virus as well as HIV-1-mediated cytopathogenesis and cell fusion at levels which are within acceptable ranges of cytotoxicity.